sorafenib has been researched along with tae226 in 3 studies
| Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (tae226) | Trials (tae226) | Recent Studies (post-2010) (tae226) |
|---|---|---|---|---|---|
| 6,520 | 730 | 5,251 | 65 | 0 | 49 |
| Protein | Taxonomy | sorafenib (IC50) | tae226 (IC50) |
|---|---|---|---|
| Chain A, FOCAL ADHESION KINASE 1 | Gallus gallus (chicken) | 0.0062 | |
| Chain A, FOCAL ADHESION KINASE 1 | Gallus gallus (chicken) | 0.0062 | |
| Chain A, FOCAL ADHESION KINASE 1 | Gallus gallus (chicken) | 0.0062 | |
| Chain A, FOCAL ADHESION KINASE 1 | Gallus gallus (chicken) | 0.0062 | |
| Aurora kinase A | Homo sapiens (human) | 0.004 | |
| Serine/threonine-protein kinase/endoribonuclease IRE1 | Homo sapiens (human) | 0.86 | |
| Epidermal growth factor receptor | Homo sapiens (human) | 0.55 | |
| Receptor tyrosine-protein kinase erbB-2 | Homo sapiens (human) | 0.71 | |
| Insulin receptor | Homo sapiens (human) | 0.036 | |
| Insulin-like growth factor 1 receptor | Homo sapiens (human) | 0.1205 | |
| Platelet-derived growth factor receptor beta | Homo sapiens (human) | 2.6 | |
| Fibroblast growth factor receptor 1 | Homo sapiens (human) | 0.75 | |
| Focal adhesion kinase 1 | Homo sapiens (human) | 0.3135 | |
| ALK tyrosine kinase receptor | Homo sapiens (human) | 0.0275 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 2 (66.67) | 2.80 |
| Authors | Studies |
|---|---|
| Hajduk, PJ; Johnson, EF; Kifle, L; Merta, PJ; Metz, JT; Soni, NB | 1 |
| Cho, H; Choi, HG; Jeon, E; Kim, ND; Kim, S; Kim, Y; Kwon, NH; Lee, J; Moon, Y; Ryu, S; Shin, I; Sim, T; Song, C; Yoon, H | 1 |
| Alisi, A; Balsano, C; Braghini, MR; Conti, AL; Crudele, A; de Billy, E; De Stefanis, C; Gnani, D; Leonetti, C; Levi Mortera, S; Marzano, V; Panera, N; Pastore, A; Pomella, S; Pompili, L; Porru, M; Putignani, L; Romito, I; Rota, R; Scarsella, M; Tartaglia, M; Vinciguerra, M | 1 |
3 other study(ies) available for sorafenib and tae226
| Article | Year |
|---|---|
Navigating the kinome.
Topics: Drug Design; Pharmacogenetics; Protein Kinases; Proteome; Systems Biology | 2011 |
Identification of Thieno[3,2-
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Drug Screening Assays, Antitumor; Female; fms-Like Tyrosine Kinase 3; Focal Adhesion Kinase 1; Humans; Mice, Inbred BALB C; Mice, Nude; Molecular Docking Simulation; Molecular Structure; Neoplasm Metastasis; Neoplasms; Phosphorylation; Protein Kinase Inhibitors; Pyrimidines; Structure-Activity Relationship; Thiophenes; Xenograft Model Antitumor Assays | 2021 |
Focal adhesion kinase inhibitor TAE226 combined with Sorafenib slows down hepatocellular carcinoma by multiple epigenetic effects.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Epigenesis, Genetic; Humans; Liver Neoplasms; Male; Mice; Mice, Inbred NOD; Morpholines; Sorafenib | 2021 |